X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (530) 530
animals (344) 344
humans (330) 330
quinazolinones - pharmacology (238) 238
male (235) 235
female (150) 150
mice (144) 144
quinazolinones - administration & dosage (144) 144
quinazolinones - therapeutic use (142) 142
rats (132) 132
quinazolinones (107) 107
pharmacology & pharmacy (106) 106
oncology (102) 102
chemistry, medicinal (84) 84
quinazolinones - chemistry (74) 74
analysis (73) 73
quinazolines - pharmacology (71) 71
quinazolinones - adverse effects (70) 70
leukemia, lymphocytic, chronic, b-cell - drug therapy (68) 68
middle aged (65) 65
disease models, animal (59) 59
inhibitor (58) 58
apoptosis (57) 57
cell line, tumor (56) 56
halofuginone (55) 55
antineoplastic agents - pharmacology (54) 54
piperidines (54) 54
piperidines - pharmacology (54) 54
structure-activity relationship (54) 54
cancer (53) 53
purines - administration & dosage (53) 53
rats, sprague-dawley (53) 53
aged (52) 52
dose-response relationship, drug (52) 52
treatment outcome (52) 52
quinazolinones - pharmacokinetics (51) 51
antineoplastic agents - therapeutic use (50) 50
idelalisib (50) 50
purines - therapeutic use (50) 50
biochemistry & molecular biology (49) 49
administration, oral (48) 48
adult (47) 47
quinazolinones - chemical synthesis (46) 46
hematology (45) 45
apoptosis - drug effects (44) 44
antineoplastic agents (43) 43
care and treatment (43) 43
chemistry, organic (43) 43
rats, wistar (43) 43
expression (42) 42
antimitotic agents (41) 41
cell biology (41) 41
quinazolines - therapeutic use (41) 41
inhibition (40) 40
abridged index medicus (39) 39
fibrosis (39) 39
chronic lymphocytic-leukemia (38) 38
drugs (37) 37
purines - adverse effects (37) 37
purines - pharmacology (37) 37
activation (36) 36
mutation (36) 36
signal transduction - drug effects (36) 36
mice, inbred c57bl (35) 35
proteins (35) 35
cell proliferation - drug effects (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
drug therapy (33) 33
health aspects (33) 33
neurosciences (33) 33
chemotherapy (32) 32
research (32) 32
signal transduction (32) 32
collagen (31) 31
molecular structure (31) 31
quinazolines - administration & dosage (31) 31
rituximab (31) 31
article (30) 30
receptor (30) 30
quinazolinone (29) 29
antineoplastic agents - administration & dosage (28) 28
i synthesis (28) 28
leukemia (28) 28
aged, 80 and over (27) 27
dacomitinib (27) 27
drug design (27) 27
medicine & public health (27) 27
therapy (27) 27
antineoplastic agents - adverse effects (26) 26
inhibitors (26) 26
piperidines - therapeutic use (26) 26
mice, inbred balb c (25) 25
pharmacology (25) 25
phosphatidylinositol 3-kinases - antagonists & inhibitors (25) 25
phosphorylation (25) 25
piperidines - administration & dosage (25) 25
oxidative stress (24) 24
pi3k (24) 24
protein kinase inhibitors - therapeutic use (24) 24
time factors (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 11/2016, Volume 128, Issue 18, pp. 2199 - 2205
Journal Article
Blood, ISSN 0006-4971, 05/2016, Volume 127, Issue 20, pp. 2411 - 2415
Journal Article
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 4, pp. e176 - e182
Summary Background A new generation of biological and targeted agents might potentially replace traditional cytotoxic agents in lymphoma. Lenalidomide plus... 
Hematology, Oncology and Palliative Medicine | MANTLE-CELL LYMPHOMA | MANAGEMENT | ANTI-CD80 MONOCLONAL-ANTIBODY | PLUS RITUXIMAB | GALIXIMAB | II TRIAL | COMBINATION | HEMATOLOGY | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Quinazolinones - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Purines - administration & dosage | Rituximab - therapeutic use | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Female | Purines - adverse effects | Purines - therapeutic use | Rituximab - adverse effects | Thalidomide - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Thalidomide - administration & dosage | Rituximab - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Maximum Tolerated Dose | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Quinazolinones - therapeutic use | Thalidomide - therapeutic use | Quinazolinones - adverse effects | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3390 - 3397
Journal Article
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3406 - 3413
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Circulation: Cardiovascular Interventions, ISSN 1941-7640, 06/2012, Volume 5, Issue 3, pp. 347 - 356
BACKGROUND—Elinogrel is the only selective, competitive and reversible platelet P2Y12 inhibitor available in both intravenous (IV) and oral formulations.... 
Pharmacokinetics | Elinogrel | Pharmacodynamics | CANGRELOR | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | TICAGRELOR | pharmacodynamics | ASPIRIN | CLOPIDOGREL | INHIBITION | THERAPY | pharmacokinetics | CLINICAL-IMPLICATIONS | PRASUGREL | elinogrel | ST-SEGMENT ELEVATION | Injections, Intravenous | Purinergic P2Y Receptor Antagonists - administration & dosage | United States | Humans | Middle Aged | Receptors, Purinergic P2Y12 - drug effects | Quinazolinones - administration & dosage | Male | Angioplasty, Balloon, Coronary - adverse effects | Purinergic P2Y Receptor Antagonists - adverse effects | Angioplasty, Balloon, Coronary - mortality | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Heart Diseases - blood | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Receptors, Purinergic P2Y12 - metabolism | Platelet Aggregation Inhibitors - adverse effects | Quinazolinones - pharmacokinetics | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Europe | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Treatment Outcome | Models, Statistical | Sulfonamides - pharmacokinetics | Ticlopidine - analogs & derivatives | Canada | Heart Diseases - mortality | Heart Diseases - therapy | Sulfonamides - adverse effects | Quinazolinones - adverse effects | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2015, Volume 33, Issue 4, pp. 895 - 900
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 07/2016, Volume 59, Issue 13, pp. 6407 - 6430
Journal Article
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 2, pp. 195 - 203
Journal Article